Reviews in Endocrine and Metabolic Disorders

, Volume 14, Issue 2, pp 119–125

Bone and vitamin D metabolism in HIV

  • Aristotle Panayiotopoulos
  • Nandini Bhat
  • Amrit Bhangoo
Article

Abstract

Human immunodeficiency virus (HIV) infection has progressed to a chronic disease and HIV positive individuals are living longer lives. This has lead to an increase in morbidity and mortality due to secondary issues, one being HIV bone disease. HIV infected pediatric and adult populations have a greater incidence in reduction of BMD as compared to the controls. Osteoporosis has been reported to be present in up to 15 % of HIV positive patients. We are starting to understand the mechanism behind the changes in HIV bone disease. Viral proteins interfere with osteoblastic activity either by direct interaction or by the inflammatory process that they induce. Anti-viral management, including highly active antiretroviral therapy (HAART), protease inhibitors, and nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) also are involved in disrupting proper bone metabolism. Vitamin D levels have strong correlation with bone disease in HIV patients, and are dependent not only to chronic disease state, but interaction of pharmacologic management and inflammatory process as well. Work up of the secondary causes of osteopenia and osteoporosis should be undertaken in all patients. DEXA scan is recommended in all post-menopausal women with HIV, all HIV infected men 50 years of age or older and in those with a history of fragility fractures regardless of age or gender. Preventive measures include adequate nutrition, calcium and Vitamin D intake daily, muscle strengthening and balance exercises to increase BMD and reduce fractures. Bisphosphonates are considered to be the first line for the treatment of HIV associated bone disease. This review will describe how the balanced mechanism of bone metabolism is interrupted by the HIV infection itself, the complications that arise from HIV/AIDS, and its treatment options.

Keywords

Hypothalamic pituitary adrenal (HPA) axis HIV AIDS Cytokines Glucocorticoids 

Abbreviations

PI

Protease inhibitors

ART

Anti-retroviral therapies

BMD

Bone mineral density

NRTI

Nucleotide reverse transcriptase inhibitor

References

  1. 1.
    2012 AIDS Epidemic Update. UNAIDS/WHOGoogle Scholar
  2. 2.
    Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–60.CrossRefPubMedGoogle Scholar
  3. 3.
    Stone B, Dockrell D, Bowman C, McCloskey E. HIV and bone disease. Arch Biochem Biophys. 2010;503:66–77.CrossRefPubMedGoogle Scholar
  4. 4.
    Amiel C, Ostertag A, Slama L, Baudoin C, N’Guyen T, Lajeunie E, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res Off J Am Soc Bone Miner Res. 2004;19:402–9.CrossRefGoogle Scholar
  5. 5.
    Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab. 2004;89:1200–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Landonio S, Quirino T, Bonfanti P, Gabris A, Boccassini L, Gulisano C, et al. Osteopenia and osteoporosis in HIV+ patients, untreated or receiving HAART. Biomed Pharmacother Biomed Pharmacother. 2004;58:505–8.Google Scholar
  7. 7.
    Mayer KH, Amorosa V, Tebas P. Bone disease and HIV Infection. Clin Infect Dis. 2006;42:108–14.CrossRefGoogle Scholar
  8. 8.
    Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis Off Publ Infect Dis Soc Am. 2003;36:482–90.CrossRefGoogle Scholar
  9. 9.
    Moore AL, Vashisht A, Sabin CA, Mocroft A, Madge S, Phillips AN, et al. Reduced bone mineral density in HIV-positive individuals. AIDS (London, England). 2001;15:1731–3.CrossRefGoogle Scholar
  10. 10.
    Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (London, England). 2000;14:F63–7.CrossRefGoogle Scholar
  11. 11.
    Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS (London, England). 2006;20:2165–74.CrossRefGoogle Scholar
  12. 12.
    Gutierrez F, Masia M. The role of HIV and antiretroviral therapy in bone disease. AIDS Rev. 2011;13:109–18.PubMedGoogle Scholar
  13. 13.
    McComsey GA, Huang JS, Woolley IJ, Young B, Sax PE, Gerber M, et al. Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management. J Int Assoc Phys AIDS Care. 2002;3:86–91. Chicago, Ill.CrossRefGoogle Scholar
  14. 14.
    McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;51:937–46.CrossRefGoogle Scholar
  15. 15.
    Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 1994;4:368–381Google Scholar
  16. 16.
    Gibellini D, De Crignis E, Ponti C, Cimatti L, Borderi M, Tschon M, et al. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFα activation. J Med Virol. 2008;80:1507–14.CrossRefPubMedGoogle Scholar
  17. 17.
    Cotter EJ, Malizia AP, Chew N, Powderly WG, Doran PP. HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retrovir. 2007;23:1521–30.CrossRefPubMedGoogle Scholar
  18. 18.
    Cotter EJ, Mallon PW, Doran PP. Is PPARgamma a prospective player in HIV-1-associated bone disease? PPAR Res. 2009;2009:421376.CrossRefPubMedGoogle Scholar
  19. 19.
    Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem. 2003;278:48251–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest. 2005;115:282–90.PubMedGoogle Scholar
  21. 21.
    Hittinger G, Poggi C, Delbeke E, Profizi N, Lafeuillade A. Correlation between plasma levels of cytokines and HIV-1 RNA copy number in HIV-infected patients. Infection. 1998;26:100–3.CrossRefPubMedGoogle Scholar
  22. 22.
    Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS (London, England). 2009;23:1519–29.CrossRefGoogle Scholar
  23. 23.
    Malizia AP, Cotter E, Chew N, Powderly WG, Doran PP. HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. AIDS Res Hum Retrovir. 2007;23:243–50.CrossRefPubMedGoogle Scholar
  24. 24.
    Wang MW, Wei S, Faccio R, Takeshita S, Tebas P, Powderly WG, et al. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest. 2004;114:206–13.PubMedGoogle Scholar
  25. 25.
    van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS (London, England). 2009;23:1367–76.CrossRefGoogle Scholar
  26. 26.
    Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA Am Med Assoc. 2004;292:191–201.CrossRefGoogle Scholar
  27. 27.
    McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791–801.CrossRefPubMedGoogle Scholar
  28. 28.
    Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92:4–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Kim JH, Gandhi V, Psevdos Jr G, Espinoza F, Park J, Sharp V. Evaluation of vitamin D levels among HIV-infected patients in New York City. AIDS Res Hum Retrovir. 2012;28:235–41.CrossRefPubMedGoogle Scholar
  30. 30.
    Schrumpf JA, van Sterkenburg MA, Verhoosel RM, Zuyderduyn S, Hiemstra PS. Interleukin 13 exposure enhances vitamin D-mediated expression of the human cathelicidin antimicrobial peptide 18/LL-37 in bronchial epithelial cells. Infect Immun. 2012;80:4485–94.CrossRefPubMedGoogle Scholar
  31. 31.
    Wasserman P, Rubin DS. Highly prevalent vitamin D deficiency and insufficiency in an urban cohort of HIV-infected men under care. AIDS Patient Care STDs. 2010;24:223–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Mora S, Zamproni I, Giacomet V, Cafarelli L, Figini C, Vigano A. Analysis of bone mineral content in horizontally HIV-infected children naive to antiretroviral treatment. Calcif Tissue Int. 2005;76:336–40.CrossRefPubMedGoogle Scholar
  33. 33.
    Jacobson DL, Spiegelman D, Duggan C, Weinberg GA, Bechard L, Furuta L, et al. Predictors of bone mineral density in human immunodeficiency virus-1 infected children. J Pediatr Gastroenterol Nutr. 2005;41:339–46.CrossRefPubMedGoogle Scholar
  34. 34.
    Jacobson DL, Lindsey JC, Gordon CM, Moye J, Hardin DS, Mulligan K, et al. Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS. 2010;24:687–96.CrossRefPubMedGoogle Scholar
  35. 35.
    Mulligan K, Harris DR, Emmanuel P, Fielding RA, Worrell C, Kapogiannis BG, et al. Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: adolescent trials network study 021B. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;55:461–8.CrossRefGoogle Scholar
  36. 36.
    Pitukcheewanont P, Safani D, Church J, Gilsanz V. Bone measures in HIV-1 infected children and adolescents: disparity between quantitative computed tomography and dual-energy X-ray absorptiometry measurements. Osteoporos Int. 2005;16:1393–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Vigano A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS (London, England). 2001;15:1823–9.CrossRefGoogle Scholar
  38. 38.
    Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Viganò A. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab. 2004;89:24–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Mulligan K, Harris DR, Emmanuel P, Fielding RA, Worrell C, Kapogiannis BG, et al. Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: adolescent trials network study 021B. Clin Infect Dis. 2012;55:461–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Pitukcheewanont P, Safani D, Church J, Gilsanz V. Bone measures in HIV-1 infected children and adolescents: disparity between quantitative computed tomography and dual-energy X-ray absorptiometry measurements. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2005;16:1393–6Google Scholar
  41. 41.
    Watts NB, Lewiecki EM, Miller PD, Baim S, Dawson-Hughes B. National Osteoporosis Foundation 2008 Clinician’s Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist A revised clinician’s guide to the prevention and treatment of osteoporosis. J Clin Densitom. 2008;11:473–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Gregg EW, Cauley JA, Seeley DG, Ensrud KE, Bauer DC. Physical activity and osteoporotic fracture risk in older women. Study of osteoporotic fractures research group. Ann Intern Med. 1998;129:81–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, Samaras K, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis. 2009;200:1746–54.CrossRefPubMedGoogle Scholar
  44. 44.
    Gazzola L, Comi L, Savoldi A, Tagliabue L, Del Sole A, Pietrogrande L, et al. Use of the FRAX equation as first-line screening of bone metabolism alteration in the HIV-infected population. J Infect Dis. 2010;202:330–1. author reply 331–332.CrossRefPubMedGoogle Scholar
  45. 45.
    Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004;89:5387–91.CrossRefPubMedGoogle Scholar
  46. 46.
    Romagnoli E, Mascia ML, Cipriani C, Fassino V, Mazzei F, D’Erasmo E, et al. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab. 2008;93:3015–20.CrossRefPubMedGoogle Scholar
  47. 47.
    Cannell JJ, Hollis BW, Zasloff M, Heaney RP. Diagnosis and treatment of vitamin D deficiency. Expert Opin Pharmacother. 2008;9:107–18.CrossRefPubMedGoogle Scholar
  48. 48.
    Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.CrossRefPubMedGoogle Scholar
  49. 49.
    Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA J Am Med Assoc. 2010;303:1815–22.CrossRefGoogle Scholar
  50. 50.
    Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinologists. 2006;12:48–53.Google Scholar
  51. 51.
    Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore CE, Minisola S, Rossini M. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2009;20:239–244Google Scholar
  52. 52.
    Mora S, Zamproni I, Zuccotti G, Vigano A. Pediatric HIV infection and bone health: an emerging challenge. Front Biosci. 2010;2:1265–74.CrossRefGoogle Scholar
  53. 53.
    McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007;21:2473–82.CrossRefPubMedGoogle Scholar
  54. 54.
    Mondy K, Powderly WG, Claxton SA, Yarasheski KH, Royal M, Stoneman JS, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr. 2005;38:426–31.CrossRefPubMedGoogle Scholar
  55. 55.
    Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab. 2007;92:1283–8.CrossRefPubMedGoogle Scholar
  56. 56.
    Huang J, Meixner L, Fernandez S, McCutchan JA. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS. 2009;23:51–7.CrossRefPubMedGoogle Scholar
  57. 57.
    Miller PD. Is there a role for bisphosphonates in chronic kidney disease? Semin Dial. 2007;20:186–90.CrossRefPubMedGoogle Scholar
  58. 58.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–22.CrossRefPubMedGoogle Scholar
  59. 59.
    Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–301.CrossRefPubMedGoogle Scholar
  60. 60.
    Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab. 2005;90:1897–9.CrossRefPubMedGoogle Scholar
  61. 61.
    Johnell O, Kanis JA, Black DM, Balogh A, Poor G, Sarkar S, et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) study. J Bone Miner Res Off J Am Soc Bone Miner Res. 2004;19:764–72.CrossRefGoogle Scholar
  62. 62.
    Koutkia P, Canavan B, Breu J, Grinspoon S. Effects of growth hormone-releasing hormone on bone turnover in human immunodeficiency virus-infected men with fat accumulation. J Clin Endocrinol Metab. 2005;90:2154–60.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Aristotle Panayiotopoulos
    • 1
  • Nandini Bhat
    • 2
  • Amrit Bhangoo
    • 1
  1. 1.Department of Pediatric EndocrinologyChildren’s Hospital at SUNY Downstate, Kings County Hospital Center, and Infants and Children’s Hospital at MaimonidesBrooklynUSA
  2. 2.Department of PediatricsKings County Hospital Center and Children’s Hospital at SUNY DownstateBrooklynUSA

Personalised recommendations